Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Old API Wind-down Ltd - Ordinary Shares ARLZQ

"Old API Wind-down Ltd, formerly Aralez Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in the acquisition, development, and commercialization of products primarily in cardiovascular, pain management and other specialty areas. Its key products include Fiorinal, Proferrin, Fibricor, Uracyst and Neovisc, Cambia and other marketed products. The company currently operates in two geographical markets, the United States and Canada. The firm generates most of its reven


OTCPK:ARLZQ - Post by User

Comment by goldbug83on Sep 16, 2016 6:24am
82 Views
Post# 25243807

RE:RE:RE:Value of Yosprala

RE:RE:RE:Value of Yospralamjh9413 I believe it was a seekingalpha.com article just around or slighty before the time of the merger. It was multiple pages of in depth analysis on the company and Yosprala's future potential. I just hope Adams and the Warche$t (would make a great movie title) lights napalm on this company and we see multiple drug acqusitions, and strong quarterly sales growth only to be bought out and we all celebrate with hookers and blow. By the way kuatolives drunken posts we perfect. The roller coaster of riding TRX to highs (I think we both wish we had sold on) to the anxiousness of fda approval summed up no better. Kudos.
<< Previous
Bullboard Posts
Next >>